Dublin, April 18, 2023 (GLOBE NEWSWIRE) -- The "Human Growth Hormone Drugs: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Human Growth Hormone Drugs Market to Reach $4.8 Billion by 2030
The global market for Human Growth Hormone Drugs estimated at US$3.5 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 4% over the analysis period 2022-2030.
Subcutaneous, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$3.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Intramuscular segment is readjusted to a revised 3.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 5.8% CAGR
The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$358.1 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 3.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.
What`s New for 2023?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 335 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $3.5 Billion |
| Forecasted Market Value (USD) by 2030 | $4.8 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- A Prelude to Human Growth Hormones
- Recombinant Human Growth Hormones
- Evolution of Recombinant Human Growth Hormones (hGH)
- COVID-19 Impact on Human Growth Hormone Drugs
- GLOBAL MARKET OVERVIEW
- Global Human Growth Hormone Drugs Market to Witness Steady Growth
- List of Select Approved Prescription Daily-dose hGH Products by Indication
- List of Select Approved Prescription Weekly-dose hGH Products by Indication
- Subcutaneous Route Dominates Human Growth Hormone Drugs Market
- Growth Hormone Deficiency Application Leads the Human Growth Hormone Drugs Market
- North America and Europe Dominate, Asia-Pacific to Witness Fastest Growth
- Market Restraints
- Competition
- Leading Recombinant hGH Products in the Global Market (2020): Annual Sales in US$ Million for Genotropin, Humatrope, Norditropin, Nutropin and Saizen
- Global Recombinant hGH Products Market (2020): Market Share of Leading Players
- Recent Market Activity
MARKET TRENDS & DRIVERS
- High Prevalence of Growth Hormone Deficiency Disorders
- Pediatric GHD Rules, while Adult GHD Remains Underserved
- Long-Acting hGH Drugs - A Game Changer for the Human Growth Hormone Drugs Market
- Approval of Novo Nordisk's Once-Weekly Sogroya to Transform the Market Landscape
- Other Noteworthy Developments in the Long Acting hGH Space
- Patent Expiry Paves Way for the Emergence of Biosimilars
- Strong Innovation Drive Takes Hold of the hGH Industry
- Manufacturers Bet on Novel Drug Delivery Technologies
- Growing Non-Prescription/Off-Label Usage - A Potential Health Hazard
- Needle-less Drug Delivery Systems to Wipe Out of Syringes
- Drug Delivery Device Options for Marketed hGH Products
- Major Growth Restraining Factors
- Complex Delivery System
- High Cost of hGH Treatment
- Biosimilars Threaten Revenue Growth Erosion
- Select Daily and Long-Acting Human Growth Hormone Products List in Phase III Pipeline
FOCUS ON SELECT PLAYERS (Total 46 Featured)
- AnkeBio Co. Ltd
- Eli Lilly and Company
- EMD Serono Inc.
- Ferring Pharmaceuticals
- Genentech, Inc (Roche)
- GeneScience Pharmaceuticals Co. Ltd
- Ipsen S.A.
- LG Life Sciences
- Merck KGaA
- Novo Nordisk A/S
- Pfizer, Inc
- Sandoz International GmbH (Novartis AG)
- Strongbridge Biopharma
- Teva Pharmaceutical Industries, Ltd
For more information about this report visit https://www.researchandmarkets.com/r/4zcp3u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
